首页> 外文OA文献 >The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients

【2h】

The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients

机译：用曲妥珠单抗在人表皮生长因子受体2阳性转移乳腺癌患者治疗后随后治疗后治疗的存活结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
R. Watanuki; A. Shimomura; S. Yazaki; S. Narita; H. Okuma; T. Nishikawa; M. Tanioka; K. Sudo; T. Shimoi; E. Noguchi; Y. Kan; K. Tamura;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer [J] . WelslauM., DiérasV., SohnJ.-H., Cancer: A Journal of the American Cancer Society . 2014,第5期

机译：EMILIA的患者报告结果，曲妥珠单抗Emtansine（T-DM1）与卡培他滨和拉帕替尼在人表皮生长因子受体2阳性局部晚期或转移性乳腺癌中的随机3期研究
2. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. [J] . Javier Cortés, Pierre Fumoleau, Giulia Valeria Bianchi, Journal of Clinical Oncology . 2012,第14期

机译：基于曲妥珠单抗的治疗后帕妥珠单抗的单药治疗以及随后曲妥珠单抗的重新引入：晚期人类表皮生长因子受体2阳性乳腺癌患者的活性和耐受性。
3. Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study [J] . Yunchao Wang, Tao Sun, Donggui Wan, OncoTargets and therapy . 2015,第4期

机译：激素受体状态预测接受曲妥珠单抗治疗的人类表皮生长因子2阳性转移性乳腺癌患者的临床结局：一项多中心回顾性研究
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Hormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective study [O] . Yunchao Wang, Tao Sun, Donggui Wan, 2015

机译：激素受体状态预测接受曲妥珠单抗治疗的人类表皮生长因子2阳性转移性乳腺癌患者的临床结局：一项多中心回顾性研究
7. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population [O] . Shoko Noda-Narita, Akihiko Shimomura, Asuka Kawachi, 2019

机译：血液抑制患者患者曲妥珠单抗疗效的疗效比较，所述转移性人体表皮生长因子患者2阳性乳腺癌及仅在日本人群中的曲妥珠单抗治疗

The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients

著录项

引文网络

相似文献

相关主题

期刊订阅